Use of Avacopan in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and Estimated Glomerular Filtration Rate <15 ml/min per 1.73 m2

Abstract

Rapidly progressive glomerulonephritis (RPGN) represents a severe manifestation of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV), and is associated with substantial morbidity and mortality1. Kidney function following six months of therapy is predictive of future requirement of kidney replacement therapy (KRT), and patients who require KRT have the worst long-term outcomes1. Therefore, maximal recovery of kidney function is imperative to improve survival and quality of life.